Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q4 2017 · 10-K
Revenue$57.28M$57.28M+956.6% vs Q4 2016 Net Income-$24.00M-$24.00MN/M vs Q4 2016 EPS Diluted-$0.37-$0.37N/M vs Q4 2016 Operating Income-$23,147,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$34,957,000N/M Margins · derivedOperating margin-40.4%+1590.2 pt vs Q4 2016
Net margin-41.9%+1589.8 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 1, 2018 · 60 d after period end